samedan logo
 
 
spacer
home > pmps > summer 2021 > pda event preview 2021
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

PDA Event Preview 2021

4 October 2021: On this pre-conference day, the focus is on interactivity. Three workshops are dedicated to industry hot topics: smart devices and digital solutions, wearable injection devices, and combination products. These topics will be introduced with keynote presentations by subject matter experts.

Then the focus will turn to collaboration through group discussions or breakout rooms. This format not only gives the participants the opportunity to learn from each other and to get informed about industry best practices, but also lets participants bring their own questions into the discussion and get practical, relevant answers from the group.

Each of the workshops will be led and moderated by a diverse panel of experts, representing the pharmaceutical industry, suppliers, notified bodies, and regulatory authorities. This ensures that the topics can be considered from all relevant perspectives, and that the jointly developed answers and solutions are as comprehensive as possible.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
PDA Universe of Pre-Filled Syringes and Injection Devices Conference
spacer
Falk Klar
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline

Sanofi announced today an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer, with a total payment of $90 million for three years plus additional research milestone-based payments.
More info >>

White Papers

Accelerating the Time from DNA to Material

Merck

Cell line development is a critical step in upstream process development for monoclonal antibodies (mAbs). Unfortunately, the search for the bestproducing clone can be labor- and resource-intensive and is often compared with looking for a needle in a haystack. Cells must first be engineered to produce the biologic of interest and the cell line generated from a high producing clone must deliver a sufficiently high titer to support clinical studies, and ultimately commercialization of the therapeutic.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement